Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

	Complete if Known
Application Number	10/590,634-Conf. #2264
Filing Date	May 17, 2007
First Named Inventor	Bjarne Larsen
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	66123(300586)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	ADRIAN TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, and Bloom SR. Human distribution and release of a putative new gut hormone, pep-tide YY. Gastroenterology 89: 1070-1077, 1985.	
	CB	ADRAIN TE, Savage AP, Sagor GR, Allen JM, Bacarese-Hamilton AJ, Ta-temoto K, Polak JM, and Bloom SR. Effect of peptide YY on gastric, pancre-atic, and biliary function in humans. Gastroenterology 89: 494-499, 1985.	
	CC	ALLEN JM, Fitzpatrick ML, Yeats JC, Darcy K, Adrian TE, and Bloom SR. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Di-gestion 30: 255-262, 1984.	
	CD	BATTERHAM RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, and Bloom SR. Inhibition of food intake in obese subjects by pep-tide YY3-36. N Engl J Med 349: 941-948, 2003.	
	CE	BATTERHAM RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, and Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654, 2002.	
	CF	BERGLUND MM, Hipskind PA, and Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor sub-types. Exp Biol Med (Maywood) 228: 217-244, 2003.	
	CG	BROOME M, Hokfelt T, and Terenius L. Peptide YY (PYY)-immunoreactive neurons in the lower brain stem and spinal cord of rat. Acta Physiol Scand 125: 349-352, 1985.	
	CH	BROWNING KN and Travagli RA. Neuropeptide Y and peptide YY inhibit excitatory synaptic transmission in the rat dorsal motor nucleus of the vagus. J Physiol, 2003.	
	CI	CAMPBELL RE, Smith MS, Allen SE, Grayson BE, Ffrench-Mullen JM, and Grove KL. Orexin neurons express a functional pancreatic polypeptide Y4 re-ceptor. J Neurosci 23: 1487-1497, 2003.	
	CJ	CHEN CH and Rogers RC. Peptide YY and the Y2 agonist PYY-(13-36) in-hibit neurons of the dorsal motor nucleus of the vagus. Am J Physiol 273: R213-218, 1997.	
	CK	FUHLENDORFF J, Johansen NL, Melberg SG, Thogersen H, and Schwartz TW. The antiparallel pancreatic polypeptide fold in the binding of neuropep-tide Y to Y1 and Y2 receptors. J Biol Chem 265: 11706-11712, 1990.	
	CL	GRANDT D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, and Reeve JR, Jr.	

Examiner Signature _____ Date Considered _____

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/590,634-Conf. #2264
Filing Date	May 17, 2007
First Named Inventor	Bjarne Larsen
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	66123(300586)

		Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51: 151-159, 1994.	
	CM	GRANDT D, Schimiczek M, Rascher W, Feth F, Shively J, Lee TD, Davis MT, Reeve JR, Jr., and Michel MC. Neuropeptide Y 3-36 is an endogenous ligand selective for Y2 receptors. Regul Pept 67: 33-37, 1996.	
	CN	GRANDT D, Schimiczek M, Struk K, Shively J, Eysselein VE, Goebell H, and Reeve JR, Jr. Characterization of two forms of peptide YY, PYY(1-36) and PYY(3-36), in the rabbit. Peptides 15: 815-820, 1994.	
	CO	GRANDT D, Teyssen S, Schimiczek M, Reeve JR, Jr., Feth F, Rascher W, Hirche H, Singer MV, Layer P, Goebell H, and et al. Novel generation of hor-mone receptor specificity by amino terminal processing of peptide YY. Bio-chem Biophys Res Commun 186: 1299-1306, 1992.	
	CP	KIMMEL JR, Pollock HG, and Hazelwood RL. Isolation and characteriza-tion of chicken insulin. Endocrinology 83: 1323-1330, 1968.	
	CQ	LEE CC and Miller RJ. Is there really an NPY Y3 receptor? Regul Pept 75-76: 71-78, 1998.	
	CR	MARTINEZ V, Barquist E, Rivier J, and Tache Y. Central CRF inhibits gastric emptying of a nutrient solid meal in rats: the role of CRF2 recep-tors. Am J Physiol 274: G965-970, 1998.	
	CS	MEDEIROS MD and Turner AJ. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopepti-dase-24.11. Endocrinology 134: 2088-2094, 1994.	
	CT	PAPPAS TN, Debas HT, Chang AM, and Taylor IL. Peptide YY release by fatty acids is sufficient to inhibit gastric emptying in dogs. Gastroen-terology 91: 1386-1389, 1986.	
	CU	PAPPAS TN, Debas HT, and Taylor IL. Peptide YY: metabolism and ef-fect on pancreatic secretion in dogs. Gastroenterology 89: 1387-1392, 1985.	
	CV	STANLEY BG, Daniel DR, Chin AS, and Leibowitz SF. Paraventricular nucleus injections of peptide YY and neuropeptide Y preferentially enhance carbohydrate ingestion. Peptides 6: 1205-1211, 1985.	
	CW	TATEMOTO K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci U S A 79: 2514-2518, 1982.	
	CX	TATEMOTO K, Carlquist M, and Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypep-tide. Nature 296: 659-660, 1982.	
	CY	WAHLESTEDT C, Yanaihara N, and Hakanson R. Evidence for different pre- and postjunctional receptors for neuropeptide Y and related peptides. Regul Pept 13: 307-318, 1986.	
	CZ	WHITCOMB DC and Taylor IL. A new twist in the brain-gut axis. Ameri-can Journal of the Medical Sciences 304: 334-338, 1992.	

Examiner Signature		Date Considered	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/

Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/590,634-Conf. #2264
Filing Date	May 17, 2007
First Named Inventor	Bjarne Larsen
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	66123(300586)

	CA1	ALBRECHT JT and Canada TW. Cachexia and anorexia in malignancy. Hemato Oncol Clin North Am 10: 791-800, 1996.	
	CB1	NELSON KA, Walsh D, and Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 12: 213-225, 1994.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Andrew D. Kosar/	Date Considered	01/31/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ADK/